Baricitinib tablets

Baricitinib tablets

Form: Tablets

Strength: 2 mg, 4 mg

Reference Brands: Olumiant®(EU & US- Emergency Use Authorization (EUA)

Category: Arthritis

Baricitinib tablets are approved in the EU and US for moderate to severe rheumatoid arthritis. In the EU, Eli Lilly’s Olumiant is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical trial data and biosimilarity assessments. Both regions require detailed dossiers for approval and continuous pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate efficient market access for baricitinib tablets, ensuring adherence to European and American standards for safe, effective management of autoimmune diseases, helping you navigate complex regulatory landscapes seamlessly.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Pegloticase injecatble

Strength: 8 mg/1.2 mL vial

Form: Injectable (IV solution)

Reference Brands: Krystexxa (US)

View Details Get Enquiry
Colchicine tablest

Strength: 0.6 mg

Form: Tablet

Reference Brands: Colcrys(US)

View Details Get Enquiry
Febuxostat tablets

Strength: 40 mg, 80 mg

Form: Oral Tablets

Reference Brands: Uloric(EU & US)

View Details Get Enquiry
Allopurinol tablets

Strength: 100 mg, 300 mg

Form: Oral Tablets

Reference Brands: Aloprim(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.